Compare Sana Biotechnology Inc (SANA) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Simon Property Group Inc — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $1.03B), while Simon Property Group Inc trades at $206.11 (market cap $68.56B). The key difference: Simon Property Group Inc is far larger — about 66.6× Sana Biotechnology Inc's market cap, and Simon Property Group Inc pays a 4.2% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | SPG | |
|---|---|---|
Market Cap | $1.03B | $68.56B |
Sector | Health | Real Estate |
52-Week High | $5.92 | $236.70 |
52-Week Low | $2.68 | $173.35 |
Enterprise Value | $946.04M | $97.00B |
Dividend Yield | — | 4.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
SPG trades at $211.88, up 1.17% daily, with a bearish technical signal but strong fundamentals including a P/E of 14.95, robust net income margin of 66.57%, and recent Q2 2026 FFO beat. The company raised $800 million in senior notes (PRNewsWire, 2026-09-09) and launched Simon Media Network to monetize mall traffic (PRNewsWire, 2026-08-27), enhancing growth prospects despite a Q2 EPS miss.
Outlook is mixed: analyst consensus targets $231.82 with 42% buy ratings, but risks include high debt ($24.21B long-term) and bearish technicals. Opportunities lie in dividend yields and media initiatives, while headwinds involve retail real estate volatility and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
